NYSE$BMY
Bristol-Myers Squibb Co · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Bristol-Myers Squibb reported Q1 2025 total revenues of $11.2B with net earnings of $2.46B and diluted EPS of $1.20.
Total revenues were $11.2 billion for the quarter ended March 31, 2025, down 6% year over year as growth portfolio products partially offset legacy brand erosion. Net earnings attributable to BMS were $2.46 billion; diluted EPS was $1.20 versus a large year-ago loss tied to one-time items. Eliquis and oncology franchises remain core profit drivers.
- Q1 total revenues $11.2B (-6% YoY).
- Net earnings to BMS $2.46B; diluted EPS $1.20.
- Growth portfolio offset Revlimid and legacy generic headwinds.
- IRA pricing, pipeline catalysts, and M&A integration shape outlook.
Headline financials
Revenue & EPS history
Bristol-Myers Squibb · Revenue · Quarterly
$11.2B
Forward guidance
The quarterly filing discusses operating priorities, liquidity, and sector-specific risks.
Tailwinds
- Management outlines strategic priorities and capital allocation.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.9%
Avg return
30 days after
47%
34 / 73 earnings
Positive
+8.2%
Q2 2024
Best reaction
-9.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -1.1% | -0.7% | |
| Q4 2025 | +3.3% | +5.6% | +4.6% | |
| Q3 2025 | +7.1% | +7.0% | +15.5% | |
| Q2 2025 | -5.8% | -0.3% | +2.6% | |
| Q1 2025 | +0.4% | +1.4% | -3.5% | |
| Q4 2024 | -3.8% | -6.3% | +2.3% | |
| Q3 2024 | +3.2% | +6.2% | +12.5% | |
| Q2 2024 | +8.2% | +5.1% | +6.3% | |
| Q1 2024 | -8.2% | -10.1% | -15.6% | |
| Q4 2023 | -1.4% | -0.1% | +4.6% | |
| Q3 2023 | -9.9% | -9.0% | -12.1% | |
| Q2 2023 | -3.2% | -3.0% | -2.1% | |
| Q1 2023 | -1.8% | +0.1% | -6.2% | |
| Q4 2022 | +4.5% | +4.6% | -2.7% | |
| Q3 2022 | +2.0% | +5.3% | +8.4% | |
| Q2 2022 | +1.5% | -0.0% | -3.3% | |
| Q1 2022 | -2.7% | -1.2% | -1.4% | |
| Q4 2021 | +3.3% | +4.8% | +8.3% | |
| Q3 2021 | -1.9% | +0.8% | -2.9% | |
| Q2 2021 | +1.0% | +0.8% | -1.3% | |
| Q1 2021 | -5.5% | -3.2% | -0.5% | |
| Q4 2020 | -1.8% | -3.7% | -2.6% | |
| Q3 2020 | -2.5% | -1.4% | -4.8% | |
| Q2 2020 | +2.2% | +5.8% | +0.4% | |
| Q1 2020 | -0.1% | +3.6% | +0.3% | |
| Q4 2019 | +1.0% | +2.1% | -8.1% | |
| Q3 2019 | +0.5% | -0.8% | +0.1% | |
| Q2 2019 | +5.0% | +3.1% | +7.7% | |
| Q1 2019 | +2.8% | +4.1% | +4.9% | |
| Q4 2018 | -2.1% | -3.3% | +2.0% | |
| Q3 2018 | +3.3% | +2.4% | +8.4% | |
| Q2 2018 | -3.6% | -0.5% | +1.6% | |
| Q1 2018 | +1.0% | +1.8% | +2.0% | |
| Q4 2017 | -4.1% | -1.2% | +4.1% | |
| Q3 2017 | -6.3% | -3.7% | -4.0% | |
| Q2 2017 | -1.3% | +0.2% | +4.3% | |
| Q1 2017 | +4.2% | +4.1% | +0.4% | |
| Q4 2016 | -3.7% | -0.8% | +13.9% | |
| Q3 2016 | +3.5% | +3.1% | +15.6% | |
| Q2 2016 | -2.2% | -1.9% | -23.1% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -4.9% | — | — | |
| Q1 2015 | -1.3% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2014 | +2.0% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -7.8% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | +5.1% | — | — | |
| Q3 2012 | +1.5% | — | — | |
| Q2 2012 | +3.1% | — | — | |
| Q1 2012 | -0.6% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +0.2% | — | — | |
| Q1 2011 | -0.0% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q4 2007 | -1.5% | — | — | |
| Q3 2010 | -1.1% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +4.0% | — | — | |
| Q1 2010 | +0.7% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q3 2008 | -2.0% | — | — | |
| Q3 2009 | -2.0% | — | — | |
| Q4 2008 | +5.5% | — | — | |
| Q2 2008 | +5.5% | — | — | |
| Q2 2009 | +5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro